CircRNAs in lung cancer- role and clinical application.


Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
28 09 2022
Historique:
received: 22 03 2022
revised: 01 06 2022
accepted: 27 06 2022
pubmed: 6 7 2022
medline: 10 8 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

Lung cancer holds the highest mortality rate among malignancies worldwide. Nevertheless, the potential molecular mechanisms of its tumorigenesis and evolution remain obscure. Circular RNAs (circRNAs), a broad category of covalently closed molecules, follow a malignancy-restricted expression pattern. Leading-edge studies have demonstrated the clinical application prospects of circRNAs in lung cancer. Herein, this review elucidates the biogenesis, biological functions, and pathophysiology of circRNAs. Furthermore, we underscore the forefront of the diagnostic, prognostic, and therapeutic potential of circRNAs in lung cancer as well as discuss the bottleneck that needs to be overcome to translate the basic advances of circRNAs into clinical practice.

Identifiants

pubmed: 35780929
pii: S0304-3835(22)00294-4
doi: 10.1016/j.canlet.2022.215810
pii:
doi:

Substances chimiques

RNA, Circular 0
RNA 63231-63-0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

215810

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Jingwei Li (J)

Department of Respiratory and Critical Care Medicine, Med-X Center for Manufacturing, Frontiers Science Center for Disease-related Molecular Network, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.

Qiran Zhang (Q)

Department of Respiratory and Critical Care Medicine, Med-X Center for Manufacturing, Frontiers Science Center for Disease-related Molecular Network, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.

Decheng Jiang (D)

West China Medical School/West China Hospital, Sichuan University, Chengdu, China.

Jun Shao (J)

Department of Respiratory and Critical Care Medicine, Med-X Center for Manufacturing, Frontiers Science Center for Disease-related Molecular Network, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.

Weimin Li (W)

Department of Respiratory and Critical Care Medicine, Med-X Center for Manufacturing, Frontiers Science Center for Disease-related Molecular Network, West China Medical School/West China Hospital, Sichuan University, Chengdu, China. Electronic address: weimi003@scu.edu.cn.

Chengdi Wang (C)

Department of Respiratory and Critical Care Medicine, Med-X Center for Manufacturing, Frontiers Science Center for Disease-related Molecular Network, West China Medical School/West China Hospital, Sichuan University, Chengdu, China. Electronic address: chengdi_wang@scu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH